Impact of Tumor Burden Score on Conditional Survival after Curative-Intent Resection for Hepatocellular Carcinoma: A Multi-Institutional Analysis.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
accepted:
23
07
2021
pubmed:
4
8
2021
medline:
3
11
2021
entrez:
3
8
2021
Statut:
ppublish
Résumé
The impact of tumor burden score (TBS) on conditional survival (CS) among patients undergoing curative-intent resection of hepatocellular carcinoma (HCC) has not been examined to date. Patients who underwent liver resection of HCC between 2000 and 2017 were identified from a multi-institutional database. The impact of TBS and other clinicopathologic factors on 3-year conditional survival (CS Among 1,040 patients, 263 (25.3%) patients had low TBS, 668 (64.2%) had medium TBS and 109 (10.5%) had high TBS. TBS was strongly associated with OS; 5-year OS was 39.0% among patients with high TBS compared with 61.1% and 79.4% among patients with medium and low TBS, respectively (p < 0.001). While actuarial survival decreased as time elapsed from resection, CS increased over time irrespective of TBS. The largest differences between 3-year actuarial survival and CS CS rates among patients who underwent resection for HCC increased as patients survived additional years, irrespective of TBS. CS estimates can be used to provide important dynamic information relative to the changing survival probability after resection of HCC.
Sections du résumé
BACKGROUND
The impact of tumor burden score (TBS) on conditional survival (CS) among patients undergoing curative-intent resection of hepatocellular carcinoma (HCC) has not been examined to date.
METHODS
Patients who underwent liver resection of HCC between 2000 and 2017 were identified from a multi-institutional database. The impact of TBS and other clinicopathologic factors on 3-year conditional survival (CS
RESULTS
Among 1,040 patients, 263 (25.3%) patients had low TBS, 668 (64.2%) had medium TBS and 109 (10.5%) had high TBS. TBS was strongly associated with OS; 5-year OS was 39.0% among patients with high TBS compared with 61.1% and 79.4% among patients with medium and low TBS, respectively (p < 0.001). While actuarial survival decreased as time elapsed from resection, CS increased over time irrespective of TBS. The largest differences between 3-year actuarial survival and CS
CONCLUSIONS
CS rates among patients who underwent resection for HCC increased as patients survived additional years, irrespective of TBS. CS estimates can be used to provide important dynamic information relative to the changing survival probability after resection of HCC.
Identifiants
pubmed: 34341844
doi: 10.1007/s00268-021-06265-3
pii: 10.1007/s00268-021-06265-3
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3438-3448Informations de copyright
© 2021. Société Internationale de Chirurgie.
Références
Jemal A, Ward EM, Johnson CJ, et al (2017) Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst 109
Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156:477–491
doi: 10.1053/j.gastro.2018.08.065
White DL, Thrift AP, Kanwal F et al (2017) Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 152:812–820
doi: 10.1053/j.gastro.2016.11.020
Tsilimigras DI, Bagante F, Moris D et al (2019) Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer guidelines: a multi-institutional analysis of 1010 patients. Surgery 166:967–974
doi: 10.1016/j.surg.2019.08.010
Pinna AD, Yang T, Mazzaferro V et al (2018) Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg 268:868–875
doi: 10.1097/SLA.0000000000002889
European Association for the Study of the Liver (2018) Electronic address eee, european association for the study of the L EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
doi: 10.1016/j.jhep.2018.03.019
Amin MB, Greene FL, Edge SB, et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA: A Cancer J Clin. 67:93-99
Tsilimigras DI, Moris D, Hyer JM et al (2020) Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 107:854–864
doi: 10.1002/bjs.11464
Shah MM, Meyer BI, Rhee K et al (2020) Conditional survival analysis of hepatocellular carcinoma. J Surg Oncol 122(4):684–690
doi: 10.1002/jso.26049
Kurta ML, Edwards RP, Moysich KB et al (2014) Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol 32:4102–4112
doi: 10.1200/JCO.2014.55.1713
Spolverato G, Kim Y, Ejaz A et al (2015) Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients. JAMA Surg 150:538–545
doi: 10.1001/jamasurg.2015.0219
Hieke S, Kleber M, Konig C et al (2015) Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res 21:1530–1536
doi: 10.1158/1078-0432.CCR-14-2154
Park YK, Song SK, Kim BW et al (2017) Conditional survival analysis demonstrates that recurrence risk of surgically treated hepatocellular carcinoma evolves with time. J Gastrointest Surg 21:1237–1244
doi: 10.1007/s11605-017-3437-7
Cucchetti A, Piscaglia F, Cescon M et al (2012) Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Clin Cancer Res 18:4397–4405
doi: 10.1158/1078-0432.CCR-11-2663
Sasaki K, Morioka D, Conci S et al (2018) The tumor burden score: a new, “metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 267:132–141
doi: 10.1097/SLA.0000000000002064
Strasberg SM (2005) Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12:351–355
doi: 10.1007/s00534-005-0999-7
Buettner S, Margonis GA, Kim Y et al (2016) Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford) 18:510–517
doi: 10.1016/j.hpb.2016.04.001
Beal EW, Tumin D, Kabir A et al (2017) Trends in the mortality of hepatocellular carcinoma in the United States. J Gastrointest Surg 21:2033–2038
doi: 10.1007/s11605-017-3526-7
Lafaro KJ, Demirjian AN, Pawlik TM (2015) Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 24:1–17
doi: 10.1016/j.soc.2014.09.001
Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20-37
doi: 10.1016/j.jhep.2008.01.022
Yu SJ (2016) A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol 22:7–17
doi: 10.3350/cmh.2016.22.1.7
Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338
doi: 10.1055/s-2007-1007122
Kim Y, Ejaz A, Spolverato G et al (2015) Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the us gastric cancer collaborative. Ann Surg Oncol 22:557–564
doi: 10.1245/s10434-014-4116-5
Henson DE, Ries LA (1994) On the estimation of survival. Semin Surg Oncol 10:2–6
doi: 10.1002/ssu.2980100103
Zabor EC, Gonen M, Chapman PB et al (2013) Dynamic prognostication using conditional survival estimates. Cancer 119:3589–3592
doi: 10.1002/cncr.28273
Tsilimigras DI, Mehta R, Paredes AZ et al (2020) overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the milan criteria. Ann Surg 272:574–581
doi: 10.1097/SLA.0000000000004346
Cillo U, Vitale A, Grigoletto F et al (2006) Prospective validation of the barcelona clinic liver cancer staging system. J Hepatol 44:723–731
doi: 10.1016/j.jhep.2005.12.015
Zamboni BA, Yothers G, Choi M et al (2010) Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol 28:2544–2548
doi: 10.1200/JCO.2009.23.0573
Mayo SC, Nathan H, Cameron JL et al (2012) Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 118:2674–2681
doi: 10.1002/cncr.26553
Akateh C, Black SM, Conteh L et al (2019) Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 25:3704–3721
doi: 10.3748/wjg.v25.i28.3704
Wang J, He XD, Yao N et al (2013) A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 27:351–363
doi: 10.1155/2013/417894
Yamamoto M, Arii S, Sugahara K et al (1996) Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 83:336–340
doi: 10.1002/bjs.1800830313
Takayama T, Sekine T, Makuuchi M et al (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807
doi: 10.1016/S0140-6736(00)02654-4
Liao M, Zhu Z, Wang H et al (2017) Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 52:624–634
doi: 10.1080/00365521.2017.1292365
Qi X, Liu L, Wang D et al (2015) Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 6:36838–36859
doi: 10.18632/oncotarget.5426
Cucchetti A, Piscaglia F, Caturelli E et al (2009) Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 16:413–422
doi: 10.1245/s10434-008-0232-4